Table 4.
Comparison of treatments and SDI scores between SLE patients with and without thrombotic events.
| All (n = 259) | Thrombotic events (n = 27) | No event (n = 232) | P-value | |
|---|---|---|---|---|
| Medication (%) | ||||
| Mean daily prednisolone > 5 mg/day | 93 (36.2) | 20 (76.9) | 73 (31.6) | < 0.001 |
| Hydroxychloroquine > 80% during follow-up | 224 (86.5) | 22 (81.5) | 202 (87.1) | 0.422 |
| Immunosuppressive agents | 145 (56.0) | 19 (70.4) | 126 (54.3) | 0.112 |
| Cyclophosphamide | 55 (21.2) | 7 (25.9) | 48 (20.7) | 0.340 |
| ACEi or ARB | 93 (34.1) | 14 (51.9) | 79 (34.1) | 0.068 |
| Statin | 41 (15.8) | 6 (22.2) | 35 (15.1) | 0.336 |
| Anticoagulation or antiplatelet drugs | 55 (21.2) | 10 (37.0) | 45 (19.4) | 0.034 |
| SDIa | 0.99 ± 1.10 | 2.07 ± 1.43 | 0.86 ± 0.98 | < 0.001 |
aSDI was measured before development of thrombotic events or at the last visit.
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index; SLE, systemic lupus erythematosus.